November 19, 2019 / 7:03 AM / a month ago

BRIEF-Santhera Announces Publication Of Long-Term Idebenone Data From Syros Study

Nov 19 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG :

* REDUCING ANNUAL RATE OF DECLINE IN RESPIRATORY FUNCTION DURING IDEBENONE TREATMENT APPEARS TO BE CLINICALLY RELEVANT

* ANNOUNCES PUBLICATION OF LONG-TERM IDEBENONE DATA FROM SYROS STUDY IN DUCHENNE MUSCULAR DYSTROPHY

* SUSTAINED REDUCTION IN RATE OF DECLINE IN FVC%P INDICATES A POTENTIAL THERAPEUTIC BENEFIT Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below